156 related articles for article (PubMed ID: 3216030)
1. Pharmacokinetics and bioavailability of dilevalol in normotensive volunteers.
Kramer WG; Nagabhushan N; Affrime MB; Perentesis GP; Symchowicz S; Patrick JE
J Clin Pharmacol; 1988 Jul; 28(7):644-8. PubMed ID: 3216030
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of dilevalol and its conjugates in man. Assay method for plasma, blood, urine and bile samples and preliminary pharmacokinetic studies.
Neubeck M; Becker C; Henke D; Rösch W; Spahn-Langguth H; Mutschler E
Arzneimittelforschung; 1993 Sep; 43(9):953-7. PubMed ID: 8240457
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of dilevalol in normotensive and hypertensive volunteers.
Kramer WG; Perentesis G; Affrime MB; Patrick JE
Am J Cardiol; 1989 Jun; 63(19):7I-11I. PubMed ID: 2729127
[TBL] [Abstract][Full Text] [Related]
4. Secretion of dilevalol in breast milk.
Radwanski E; Nagabhushan N; Affrime MB; Perentesis G; Symchowicz S; Patrick JE
J Clin Pharmacol; 1988 May; 28(5):448-53. PubMed ID: 2899094
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of dilevalol.
Tenero DM; Bottorff MB; Given BD; Kramer WG; Affrime MB; Patrick JE; Lalonde RL
Clin Pharmacol Ther; 1989 Dec; 46(6):648-56. PubMed ID: 2598569
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.
Donnelly R; Macphee GJ
Clin Pharmacokinet; 1991 Aug; 21(2):95-109. PubMed ID: 1884570
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of dilevalol (I). Comparison of the pharmacokinetic and pharmacodynamic properties of dilevalol and labetalol after a single oral administration in healthy subjects.
Fujimura A; Ohashi K; Tsuru M; Ebihara A; Kondo K
J Clin Pharmacol; 1989 Jul; 29(7):635-42. PubMed ID: 2668352
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration.
Jaillon P; Poirier JM; Lecocq B; Jarreau C; Pays M; Richard MO; Cheymol G
Eur J Drug Metab Pharmacokinet; 1986; 11(3):233-8. PubMed ID: 3816879
[TBL] [Abstract][Full Text] [Related]
9. High-performance liquid chromatographic assay for dilevalol in human plasma and urine using a PRP-1 column and fluorimetric detection.
Alton KB; Petruzzi RF; Patrick JE
J Chromatogr; 1988 Mar; 425(2):363-72. PubMed ID: 2897376
[TBL] [Abstract][Full Text] [Related]
10. The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol.
Daneshmend TK; Roberts CJ
Br J Clin Pharmacol; 1982 Jul; 14(1):73-8. PubMed ID: 7104169
[TBL] [Abstract][Full Text] [Related]
11. Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers.
Jansat JM; Costa J; Salvà P; Fernandez FJ; Martinez-Tobed A
J Clin Pharmacol; 2002 Dec; 42(12):1303-10. PubMed ID: 12463724
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects.
Nave R; Bethke TD; van Marle SP; Zech K
Clin Pharmacokinet; 2004; 43(7):479-86. PubMed ID: 15139796
[TBL] [Abstract][Full Text] [Related]
13. Zatebradine: pharmacokinetics of a novel heart-rate-lowering agent after intravenous infusion and oral administration to healthy subjects.
Roth W; Bauer E; Heinzel G; Cornelissen PJ; van Tol RG; Jonkman JH; Zuiderwijk PB
J Pharm Sci; 1993 Jan; 82(1):99-106. PubMed ID: 8429501
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and bioavailability of drotaverine in humans.
Bolaji OO; Onyeji CO; Ogundaini AO; Olugbade TA; Ogunbona FA
Eur J Drug Metab Pharmacokinet; 1996; 21(3):217-21. PubMed ID: 8980918
[TBL] [Abstract][Full Text] [Related]
15. The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers.
Carchman SH; Crowe JT; Wright GJ
J Clin Pharmacol; 1987 Oct; 27(10):762-7. PubMed ID: 3323255
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability of labetalol in patients with end-stage renal disease.
Luke DR; Awni WM; Halstenson CE; Opsahl JA; Matzke GR
Ther Drug Monit; 1992 Jun; 14(3):203-8. PubMed ID: 1412606
[TBL] [Abstract][Full Text] [Related]
17. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man.
Trausch B; Oertel R; Richter K; Gramatté T
Biopharm Drug Dispos; 1995 Jul; 16(5):403-14. PubMed ID: 8527689
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of dilevalol (II). The pharmacokinetic, pharmacodynamic, and tolerance studies of dilevalol during repeated administration in healthy subjects.
Fujimura A; Ohashi K; Tsuru M; Ebihara A; Kondo K
J Clin Pharmacol; 1989 Jul; 29(7):643-9. PubMed ID: 2760257
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
Heikkinen H; Saraheimo M; Antila S; Ottoila P; Pentikäinen PJ
Eur J Clin Pharmacol; 2001; 56(11):821-6. PubMed ID: 11294372
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects.
Wiesel FA; Alfredsson G; Ehrnebo M; Sedvall G
Eur J Clin Pharmacol; 1980 May; 17(5):385-91. PubMed ID: 7418717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
